Skip to content

Treatment of Post-SCI Hypotension

Treatment of Post-SCI Hypotension: A Randomized Controlled Study of Usual Care Versus Anti Hypotension Therapy

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02919917
Enrollment
66
Registered
2016-09-30
Start date
2017-06-01
Completion date
2021-09-01
Last updated
2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Hypotension, Cerebral Blood Flow, Blood Pressure, Venous Occlusion Plethysmography

Brief summary

While treatment strategies for OH have been identified for use in persons with acute SCI, the field of SCI medicine lacks a gold standard for treatment thresholds and well-defined outcome parameters. Comprehensively documenting the impact of orthostatic hypotension (OH), regardless of symptoms, during acute rehabilitation and identifying the effects of two different treatment approaches on therapy participation and adherence to an intended rehabilitation plan could have a significant impact on clinical practice in the acute rehabilitation setting following SCI.

Detailed description

Baseline Testing: Subjects will visit the testing laboratory on the SCI Rehabilitation Unit for baseline data collection, prior to initiation of the treatment protocol. Upon arrival, subjects will be placed in the supine position on an adjustable surface for instrumentation, which will be conducted in a quiet, dimly lit, thermo-neutral testing environment. After a 20-minute period of quiet rest, a 10-minute sample of supine heart rate (HR), respiratory rate, BP and CBF velocity data will be collected. Venous occlusion plethysmography (Vop) will be collected in the supine position for two 5-minute periods. After the supine data collection, subjects will be passively moved into the seated position, with the knees and hips at 90°, for the 10-minute seated data collection period. Subjects will be asked to complete two surveys related to AD and OH symptomology. Finally, subjects will be fitted with a 24-hour HR and BP monitor and will be asked to go about their normal routine. A record of all daily activities including rehabilitation, medications, eating and sleep/wake times will be logged. This testing session should take approximately 1 hour. Daily Testing: Every day supine and seated BP measurements will be performed at least three times per day. These BP assessments will be recorded in the supine and seated positions in the subject's room by a patient care associate who is blind to the study arm allocation. For every scheduled physical and occupational therapy session, the treating therapist will be asked to complete a brief 6 question survey to document if that session was altered, disrupted, or missed due to hypotension (Therapist Reported Version). The subject will also be asked to complete a brief survey to determine if from their perspective the session was altered, disrupted or missed due to hypotension (Subject Reported Version). In addition, every day a co-investigator and the attending physician for that subject will complete an EMR review of queried BP values within the previous 24 hours, symptoms of low BP, adverse events related to high or low BP, and will review (and act upon for the usual care arm) the protocol treatment decision tree. Weekly Testing: At weekly intervals of between 6 and 8 days, subjects will be asked to visit the testing laboratory on the SCI Rehabilitation Unit. Procedures for the weekly testing sessions will be the same as for the Baseline Testing. The 24-hour BP assessment will be conducted twice weekly. Discharge Testing: At discharge subjects will undergo similar testing as described during the Baseline and Weekly Testing with the addition of the Patient Global Impression of Change survey, which will be administered by the Mount Sinai Site Research Assistant.

Interventions

Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d

Sponsors

Icahn School of Medicine at Mount Sinai
CollaboratorOTHER
James J. Peters Veterans Affairs Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)

Masking description

Therapists administering rehabilitation will be blinded to the randomization of patients enrolled in the study.

Intervention model description

Newly injured individuals with SCI will be eligible to participate if they demonstrate hypotension (systolic blood pressure \</= 110 mmHg in males or \</= 100 mmHg in females) upon admission to acute in-patient rehabilitation at Mount Sinai Medical Center, New York, NY. Eligible participants will be randomized to usual care (administered anti-hypotensive therapy only if they demonstrate symptoms of hypotension: dizziness, lightheadedness, nausea, blurred vision, syncope) or treatment of hypotension based on a systolic blood pressure below the hypotensive threshold. Time spent in active rehabilitation program will be compared between the usual care and treatment groups.

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
Yes

Inclusion criteria

* Any level of injury; * Any AIS grade of SCI; * Non-ventilator dependent * Primarily wheelchair dependent for mobility; * Duration of injury \< 1 year * Systolic BP less than 110 mmHg and/or diastolic BP less than 70 mmHg for males. * Systolic BP less than 100 mmHg and/or diastolic BP less than 70 mmHg for females * Primary Language is English. * Able to provide informed consent

Exclusion criteria

* Have insufficient mental capacity to independently provide informed consent * Have insufficient English speaking or reading ability to provide informed consent or complete assessments in English * Have contraindications to the use of midodrine hydrochloride * Are pregnant

Design outcomes

Primary

MeasureTime frameDescription
Affected Therapy SessionsInpatient hospitalization (up to 4 months)Responses to the questions was the therapy session affected by low BP or concern for low BP development? between the usual care and BP threshold treatment groups. The percent of sessions with a yes response are reported.
Systolic Blood PressureInpatient hospitalization (up to 4 months)Systolic hypertension (\>/= 140 mmHg)

Secondary

MeasureTime frameDescription
Systolic Blood PressureInpatient Hospitalizations (up to 4 months)Systolic hypotension (males: \< 110 mmHg; females: \< 100 mmHg)
Missed Therapy SessionsInpatient Hospitalizations (up to 4 months)Percentages of missed therapy sessions, due to low BP or concern for low BP development, in the usual care and BP treatment groups

Countries

United States

Participant flow

Participants by arm

ArmCount
Usual Care Group
Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit. Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine . Midodrine Hydrochloride: Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
29
BP Threshold Treatment Group
Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay. This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.). If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg. Midodrine Hydrochloride: Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
25
Total54

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject48

Baseline characteristics

CharacteristicBP Threshold Treatment GroupTotalUsual Care Group
Age, Categorical
<=18 years
1 Participants1 Participants0 Participants
Age, Categorical
>=65 years
3 Participants9 Participants6 Participants
Age, Categorical
Between 18 and 65 years
21 Participants44 Participants23 Participants
Age, Continuous41.97 years
STANDARD_DEVIATION 15.84
43.89 years
STANDARD_DEVIATION 16.67
45.82 years
STANDARD_DEVIATION 17.49
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants8 Participants5 Participants
Race (NIH/OMB)
Black or African American
7 Participants15 Participants8 Participants
Race (NIH/OMB)
More than one race
5 Participants11 Participants6 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants20 Participants10 Participants
Region of Enrollment
United States
25 participants54 participants29 participants
Sex: Female, Male
Female
6 Participants11 Participants5 Participants
Sex: Female, Male
Male
19 Participants43 Participants24 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 290 / 25
other
Total, other adverse events
0 / 290 / 25
serious
Total, serious adverse events
0 / 290 / 25

Outcome results

Primary

Affected Therapy Sessions

Responses to the questions was the therapy session affected by low BP or concern for low BP development? between the usual care and BP threshold treatment groups. The percent of sessions with a yes response are reported.

Time frame: Inpatient hospitalization (up to 4 months)

ArmMeasureValue (NUMBER)
Usual Care GroupAffected Therapy Sessions16.4 percentage of sessions
BP Threshold Treatment GroupAffected Therapy Sessions10.9 percentage of sessions
Primary

Systolic Blood Pressure

Systolic hypertension (\>/= 140 mmHg)

Time frame: Inpatient hospitalization (up to 4 months)

ArmMeasureValue (NUMBER)
Usual Care GroupSystolic Blood Pressure4.8 percentage of BP assessments
BP Threshold Treatment GroupSystolic Blood Pressure5.3 percentage of BP assessments
Secondary

Missed Therapy Sessions

Percentages of missed therapy sessions, due to low BP or concern for low BP development, in the usual care and BP treatment groups

Time frame: Inpatient Hospitalizations (up to 4 months)

ArmMeasureValue (NUMBER)
Usual Care GroupMissed Therapy Sessions58.60 percentage of missed therapy sessions
BP Threshold Treatment GroupMissed Therapy Sessions65.8 percentage of missed therapy sessions
Secondary

Systolic Blood Pressure

Systolic hypotension (males: \< 110 mmHg; females: \< 100 mmHg)

Time frame: Inpatient Hospitalizations (up to 4 months)

ArmMeasureValue (NUMBER)
Usual Care GroupSystolic Blood Pressure39.7 percentage of BP assessments
BP Threshold Treatment GroupSystolic Blood Pressure43.0 percentage of BP assessments

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026